Change in medical spending attributable to diabetes: national data from 1987 to 2011
- PMID: 25592194
- DOI: 10.2337/dc14-1687
Change in medical spending attributable to diabetes: national data from 1987 to 2011
Abstract
Objective: Diabetes care has changed substantially in the past 2 decades. We examined the change in medical spending and use related to diabetes between 1987 and 2011.
Research design and methods: Using the 1987 National Medical Expenditure Survey and the Medical Expenditure Panel Surveys in 2000-2001 and 2010-2011, we compared per person medical expenditures and uses among adults ≥ 18 years of age with or without diabetes at the three time points. Types of medical services included inpatient care, emergency room (ER) visits, outpatient visits, prescription drugs, and others. We also examined the changes in unit cost, defined by the expenditure per encounter for medical services.
Results: The excess medical spending attributed to diabetes was $2,588 (95% CI, $2,265 to $3,104), $4,205 ($3,746 to $4,920), and $5,378 ($5,129 to $5,688) per person, respectively, in 1987, 2000-2001, and 2010-2011. Of the $2,790 increase, prescription medication accounted for 55%; inpatient visits accounted for 24%; outpatient visits accounted for 15%; and ER visits and other medical spending accounted for 6%. The growth in prescription medication spending was due to the increase in both the volume of use and unit cost, whereas the increase in outpatient expenditure was almost entirely driven by more visits. In contrast, the increase in inpatient and ER expenditures was caused by the rise of unit costs.
Conclusions: In the past 2 decades, managing diabetes has become more expensive, mostly due to the higher spending on drugs. Further studies are needed to assess the cost-effectiveness of increased spending on drugs.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Similar articles
-
Trends in health care expenditures, utilization, and health status among US adults with spine problems, 1997-2006.Spine (Phila Pa 1976). 2009 Sep 1;34(19):2077-84. doi: 10.1097/BRS.0b013e3181b1fad1. Spine (Phila Pa 1976). 2009. PMID: 19675510
-
Health Care Spending on Diabetes in the U.S., 1996-2013.Diabetes Care. 2018 Jul;41(7):1423-1431. doi: 10.2337/dc17-1376. Epub 2018 May 10. Diabetes Care. 2018. PMID: 29748431 Free PMC article.
-
Contribution of preventable acute care spending to total spending for high-cost Medicare patients.JAMA. 2013 Jun 26;309(24):2572-8. doi: 10.1001/jama.2013.7103. JAMA. 2013. PMID: 23797716
-
Economic costs of diabetes in the U.S. In 2007.Diabetes Care. 2008 Mar;31(3):596-615. doi: 10.2337/dc08-9017. Diabetes Care. 2008. PMID: 18308683 Review.
-
Hong Kong's domestic health spending--financial years 1989/90 through 2004/05.Hong Kong Med J. 2008 Apr;14 Suppl 2:2-23. Hong Kong Med J. 2008. PMID: 18587162 Review.
Cited by
-
Inequality of opportunity in outpatient expenditure among the elderly with multimorbidity: evidence from China.Int J Equity Health. 2023 Aug 14;22(1):153. doi: 10.1186/s12939-023-01953-z. Int J Equity Health. 2023. PMID: 37580728 Free PMC article.
-
Healthcare use among people with diabetes mellitus in Europe: a population-based cross-sectional study.Fam Med Community Health. 2022 Nov;10(4):e001700. doi: 10.1136/fmch-2022-001700. Fam Med Community Health. 2022. PMID: 36357008 Free PMC article.
-
Trends in add-on medications following metformin monotherapy for type 2 diabetes.J Manag Care Spec Pharm. 2022 Nov;28(11):1253-1259. doi: 10.18553/jmcp.2022.28.11.1253. J Manag Care Spec Pharm. 2022. PMID: 36282929 Free PMC article.
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.Ann Intern Med. 2022 Oct;175(10):1392-1400. doi: 10.7326/M21-2941. Epub 2022 Oct 4. Ann Intern Med. 2022. PMID: 36191315 Free PMC article.
-
Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.Cardiovasc Diabetol. 2022 Aug 27;21(1):166. doi: 10.1186/s12933-022-01603-8. Cardiovasc Diabetol. 2022. PMID: 36030198 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
